According to a new report, published by KBV research, The Global Antibody Therapeutics Market size is expected to reach $631.3 billion by 2030, rising at a market growth of 14.4% CAGR during the forecast period.
The Subcutaneous segment is exhibiting a CAGR of 14.9% during (2023 - 2030). Subcutaneous administration is generally less invasive than intravenous administration, providing a more comfortable experience for patients. This can contribute to increased patient satisfaction and adherence to treatment regimens. The convenience of subcutaneous administration can improve patient's quality of life, allowing them to integrate treatment into their daily routines more seamlessly. This is particularly important for individuals managing chronic conditions. Subcutaneous administration can offer shorter infusion times compared to intravenous administration. This efficiency can be advantageous for patients and healthcare providers, especially in outpatient or ambulatory care settings.
The Monoclonal Antibody segmenat is generating the highest revenue in the Global Antibody Therapeutics Market by Format in 2022; thereby, achieving a market value of $451.1 billion by 2030. Autoimmune diseases characterized by an immune system attack on bodily tissues are managed with monoclonal antibodies. Drugs like adalimumab (Humira) and infliximab (Remicade) target inflammatory pathways and have been successful in conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel diseases. Monoclonal antibodies targeting specific factors involved in cardiovascular diseases have been investigated. Evolocumab and alirocumab target PCSK9 and are used to lower cholesterol levels, lowering the risk of cardiovascular events.
The Chimeric segment is anticipating a CAGR of 15.1% during (2023 - 2030). Chimeric antibodies often exhibit improved pharmacokinetic properties compared to fully non-human antibodies. This can result in longer circulating half-lives and, consequently, less frequent dosing requirements. Chimeric antibodies have been developed for various therapeutic applications, including cancer treatment, autoimmune diseases, and inflammatory disorders. Their versatility has contributed to their widespread use in different medical fields. Chimeric antibodies often combine with other therapeutic agents, such as chemotherapy or targeted therapies. Their combination with different treatment modalities contributes to enhanced therapeutic outcomes.
The Hospitals segment is leading the Global Antibody Therapeutics Market by End User in 2022; thereby, achieving a market value of $360.5 billion by 2030. Hospitals offer inpatient and outpatient infusion services, facilitating the administration of antibody therapeutics through intravenous or subcutaneous routes. This infrastructure supports the delivery of these therapies in various clinical settings. Hospitals typically have advanced diagnostic facilities that enable accurate disease diagnosis and monitoring. This diagnostic support is crucial for determining the appropriateness of antibody therapeutics and assessing treatment response. Antibody therapeutics are often used in the inpatient setting for the treatment of severe or acute conditions, such as certain cancers and autoimmune crises. Hospitals provide the necessary infrastructure for the management of critically ill patients.
The Autoimmune & Inflammatory Diseases segment is registering a CAGR of 12.9% during (2023 - 2030). Antibody therapeutics treat many autoimmune diseases, like rheumatoid arthritis, psoriasis, lupus, Crohn's disease, and multiple sclerosis. The versatility of antibodies enables their application across diverse autoimmune conditions. Antibody therapeutics has demonstrated efficacy in treating psoriasis and other dermatological conditions. Drugs like ustekinumab and secukinumab target specific cytokines involved in the skin inflammation characteristic of these conditions. Antibody therapeutics are explored for the treatment of neurological disorders with an autoimmune component, including multiple sclerosis. Drugs such as natalizumab and ocrelizumab modulate immune responses and reduce inflammation in the central nervous system.
The North America region dominated the Global Antibody Therapeutics Market by Region in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $231.6 billion by 2030. The Europe region would register a CAGR of 14% during (2023 - 2030). Additionally, The Asia Pacific region is experiencing a CAGR of 15.3% during (2023 - 2030).
Full Report: https://www.kbvresearch.com/antibody-therapeutics-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country-wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of F. Hoffmann-La Roche Ltd, AbbVie, Inc., Johnson & Johnson (Johnson & Johnson Services, Inc.), Merck KGaA, Bristol Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Novartis AG, Biogen, Inc. and Amgen, Inc.
By Route of Administration
By Format
By Source
By End User
By Disease Areas
By Geography
Companies Profiled
Unique Offerings 
